Logo image of NDRA

ENDRA LIFE SCIENCES INC (NDRA) Stock Fundamental Analysis

NASDAQ:NDRA - Nasdaq - US29273B5003 - Common Stock - Currency: USD

3.23  +0.02 (+0.62%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NDRA. NDRA was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While NDRA has a great health rating, there are worries on its profitability. NDRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NDRA had negative earnings in the past year.
NDRA had a negative operating cash flow in the past year.
NDRA had negative earnings in each of the past 5 years.
In the past 5 years NDRA always reported negative operating cash flow.
NDRA Yearly Net Income VS EBIT VS OCF VS FCFNDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

NDRA's Return On Assets of -258.47% is on the low side compared to the rest of the industry. NDRA is outperformed by 95.77% of its industry peers.
NDRA has a Return On Equity of -449.46%. This is amonst the worse of the industry: NDRA underperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROIC N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
NDRA Yearly ROA, ROE, ROICNDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

NDRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NDRA Yearly Profit, Operating, Gross MarginsNDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for NDRA has been increased compared to 1 year ago.
The number of shares outstanding for NDRA has been increased compared to 5 years ago.
NDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NDRA Yearly Shares OutstandingNDRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
NDRA Yearly Total Debt VS Total AssetsNDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NDRA has an Altman-Z score of -39.21. This is a bad value and indicates that NDRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -39.21, NDRA is not doing good in the industry: 91.53% of the companies in the same industry are doing better.
There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -39.21
ROIC/WACCN/A
WACCN/A
NDRA Yearly LT Debt VS Equity VS FCFNDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

NDRA has a Current Ratio of 5.67. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.67, NDRA belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.
A Quick Ratio of 5.67 indicates that NDRA has no problem at all paying its short term obligations.
NDRA has a better Quick ratio (5.67) than 85.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
NDRA Yearly Current Assets VS Current LiabilitesNDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.31% over the past year.
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NDRA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NDRA Yearly Revenue VS EstimatesNDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2021 2022 2025 500K 1M
NDRA Yearly EPS VS EstimatesNDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NDRA. In the last year negative earnings were reported.
Also next year NDRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDRA Price Earnings VS Forward Price EarningsNDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDRA Per share dataNDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

NDRA's earnings are expected to grow with 35.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.15%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NDRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENDRA LIFE SCIENCES INC

NASDAQ:NDRA (5/16/2025, 9:37:12 AM)

3.23

+0.02 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30
Earnings (Next)08-20 2025-08-20
Inst Owners0.02%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap1.81M
Analysts82.86
Price Target76.5 (2268.42%)
Short Float %21.75%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-90.5
EYN/A
EPS(NY)-15.69
Fwd EYN/A
FCF(TTM)-17.11
FCFYN/A
OCF(TTM)-17.05
OCFYN/A
SpS0
BVpS4.57
TBVpS4.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -258.47%
ROE -449.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -39.21
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)84.66%
Cap/Depr(5y)76.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.42%
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.22%
OCF growth 3YN/A
OCF growth 5YN/A